These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 20971518)

  • 1. Identifying and validating biomarkers for Alzheimer's disease.
    Humpel C
    Trends Biotechnol; 2011 Jan; 29(1):26-32. PubMed ID: 20971518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
    Marksteiner J; Hinterhuber H; Humpel C
    Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluid biomarkers in Alzheimer's disease - current concepts.
    Rosén C; Hansson O; Blennow K; Zetterberg H
    Mol Neurodegener; 2013 Jun; 8():20. PubMed ID: 23800368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.
    Gisslén M; Krut J; Andreasson U; Blennow K; Cinque P; Brew BJ; Spudich S; Hagberg L; Rosengren L; Price RW; Zetterberg H
    BMC Neurol; 2009 Dec; 9():63. PubMed ID: 20028512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?
    Veerabhadrappa B; Delaby C; Hirtz C; Vialaret J; Alcolea D; Lleó A; Fortea J; Santosh MS; Choubey S; Lehmann S
    Crit Rev Clin Lab Sci; 2020 Mar; 57(2):99-113. PubMed ID: 31661652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application.
    Yang J; Jia L; Li Y; Qiu Q; Quan M; Jia J
    J Alzheimers Dis; 2021; 81(1):19-32. PubMed ID: 33749646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease.
    Winder Z; Wilcock D; Jicha GA
    Clin Lab Med; 2020 Sep; 40(3):289-303. PubMed ID: 32718500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
    Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K
    J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory biomarkers in Alzheimer's disease.
    Steinerman JR; Honig LS
    Curr Neurol Neurosci Rep; 2007 Sep; 7(5):381-7. PubMed ID: 17764627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia.
    Nägga K; Gottfries J; Blennow K; Marcusson J
    Dement Geriatr Cogn Disord; 2002; 14(4):183-90. PubMed ID: 12411760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological markers of Alzheimer's disease.
    de Souza LC; Sarazin M; Teixeira-Júnior AL; Caramelli P; Santos AE; Dubois B
    Arq Neuropsiquiatr; 2014 Mar; 72(3):227-31. PubMed ID: 24676441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.
    Blennow K; Hampel H; Weiner M; Zetterberg H
    Nat Rev Neurol; 2010 Mar; 6(3):131-44. PubMed ID: 20157306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?
    Travassos M; Santana I; Baldeiras I; Tsolaki M; Gkatzima O; Sermin G; Yener GG; Simonsen A; Hasselbalch SG; Kapaki E; Mara B; Cunha RA; Agostinho P; Blennow K; Zetterberg H; Mendes VM; Manadas B; de Mendon A
    J Alzheimers Dis; 2015; 47(4):1069-78. PubMed ID: 26401784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.
    Mattsson-Carlgren N; Palmqvist S; Blennow K; Hansson O
    Nat Commun; 2020 Dec; 11(1):6252. PubMed ID: 33288742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of mild cognitive impairment and Alzheimer's disease.
    Tang BL; Kumar R
    Ann Acad Med Singap; 2008 May; 37(5):406-10. PubMed ID: 18536828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
    Andreasen N; Vanmechelen E; Vanderstichele H; Davidsson P; Blennow K
    Acta Neurol Scand Suppl; 2003; 179():47-51. PubMed ID: 12603251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.